# Haian Fu Team 2022 highlights

Yuhong Du, Associate Professor (ECBDC, Asc Director) Andrey Ivanov, Assistant Professor (ECBDC, Compt chem/bio) Xiulei Mo, Assistant Professor (Mo lab: Kenny Ouyang, Thuriah Abadi)

Qiankun Niu, Instructor; Eric Miller, Instructor

Dacheng Fan, Qianjin Li, Dongxue Wang, Min Qui, Elizabeth Zoeller, Yoon Hyeun Oum (BDCI)

# New PhDs: Sean Dovle Ph


Sean Doyle, PhD Danielle Cicka, PhD

### Training completed:

Kun Qian Changfa Shu Alafate Wahafu Xuan Novak Yang















## Notable papers:

Mo, Niu, Ivanov *et al.* (2022) Systematic discovery of mutation-directed neo-protein interactions in cancer *Cell* 185 (11), 1974-1985

Tang, Mo *et al.* (2021) Hypomorph mutation-directed small-molecule protein-protein interaction inducers <u>Cell Chem Bio</u> 28 (5), 636-647 Hahn *et al*,(2021) An expanded universe of cancer targets, <u>Cell</u> 184, 5

### Patents:

Ye, Fu, Du, issued Tang, Mo, Fu, pending Liotta, Miller, pending







# Major grants:

U01 Systematic discovery of neo-PPIs in cancer (Fu/Du/Mo/Ivanov/Niu)

R37 Discovery of small molecule mutant SMAD4-PPI inducers (Mo)

P01 Immunotherapy resistance in LUAD (Fu/Ramalingam/Mo/Ivanov)

P50 Emory Lung cancer SPORE (Ramalingam/Fu/Ivanov/Mo)

U54 Open Drug Discovery Center for AD (Levey/Fu/Du/Ivanov)

Mary Kay Ash Foundation award (Ivanov)

Biolocity: CXCR4 antagonists for RCC (Miller/Liotta/Petros/Kissick)

#### External activities:

- Chair, Board of Directors, International Chemical Biology Society (ICBS) (Fu)
- Chair, Board of Directors, PiVista Therapeutics Inc (Fu)
- Chair, ICBS Communications Committee (Ivanov)